| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 155.7MM | +10% |
| Gross Profit | 67.6MM | - |
| Cost Of Revenue | 88.1MM | -16% |
| Operating Income | -887K | -118% |
| Operating Expenses | 68.5MM | - |
| Net Income | -25.5MM | -240% |
| R&D | 10.3MM | -3% |
| G&A | 57.5MM | +4% |
| Amortization | 8.7MM | +16% |
| Interest Expense | 1.1MM | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]
Webcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ETWALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2024 financial results on Wednesday, May 1, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- month reporting period ended March 31, 2024. Th
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. In the first quarter, the fund’s Investor Class fund ARTMX returned 10.41%, Advisor Class fund APDMX posted a return of 10.40%, and Institutional Class fund APHMX returned 10.44%, compared […]
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This appointment expands the size of Repligen’s board from eight to nine members. Ms. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies. This includes eight years with Thermo Fisher Scientific, where, from 2016–2020, she ser
It is hard to get excited after looking at Repligen's (NASDAQ:RGEN) recent performance, when its stock has declined...
Repligen Corp (NASDAQ:RGEN), a bioprocessing company focused on the development, manufacture, and commercialization of products used in the process of drug manufacturing, has reported an insider sale according to a recent SEC filing.
PBYI vs. RGEN: Which Stock Is the Better Value Option?
Repligen Corp (NASDAQ:RGEN) COO James Bylund has sold a total of 4,373 shares of the company on February 23, 2024, according to a recent SEC Filing.
Key Insights Using the 2 Stage Free Cash Flow to Equity, Repligen fair value estimate is US$189 Repligen's US$197 share...
Unveiling the Financial and Strategic Position of Repligen Corp in the Bioprocessing Landscape